Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The effectiveness of mother-to-child block of CHB in pregnant women in the middle and later
stages of pregnancy has been recognized by the guidelines. TAF, as a newly marketed antiviral
drug, has not been conclusively concluded in terms of its efficacy and postpartum safety in
preventing mother-to-child transmission in pregnant women.Our purpose is to explore the TAF
for CHB the curative effect of pregnant and postnatal security.